Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$185.68 USD

185.68
1,137,205

+0.90 (0.49%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights Oracle, Union Pacific, Ford Motor, Biogen and Expedia Group

Oracle, Union Pacific, Ford Motor, Biogen and Expedia Group have been included in this Analyst Blog.

Ionis (IONS) Q1 Earnings & Sales Beat Estimates, Stock Rises

Ionis (IONS) incurs a narrower-than-expected loss in Q1. Its sales also come ahead of estimates. Stock moves up in response to the results.

Sheraz Mian headshot

Analyst Upgrades and Research Reports for Oracle, Union Pacific, Ford & Others

Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), Union Pacific Corporation (UNP), and Ford Motor Company (F).

Biotech Stock Roundup: BIIB & GILD's Earnings Update, VRTX Down on Regulatory News

Earnings and regulatory updates from Bristol Myers (BMY), among others, and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.

Biogen (BIIB) Q1 Earnings Miss, Aduhelm Setback Leads to Rejig

Biogen (BIIB) misses first-quarter estimates for earnings but beats the same for sales. Following no medicare beneficiary access to Aduhelm, Biogen initiates a cost-savings program.

Biogen Inc. (BIIB) Q1 Earnings Miss Estimates

Biogen Inc. (BIIB) delivered earnings and revenue surprises of -17.91% and 1.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More

Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.

The Zacks Analyst Blog Highlights Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen

Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen have been included in this Analyst Blog.

Pfizer (PFE) to Report Q1 Earnings: What's in the Cards?

Revenues from the COVID-19 vaccine and COVID pill, Paxlovid are likely to have driven Pfizer's (PFE) sales in the first quarter.

AbbVie (ABBV) Q1 Earnings Top, Competition Rises for Imbruvica

AbbVie (ABBV) beats estimates for first-quarter 2022 earnings while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares decline.

Indrajit Bandyopadhyay headshot

5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates

Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.

Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know

Biogen Inc. (BIIB) closed at $210.41 in the latest trading session, marking a +1.68% move from the prior day.

Zosano (ZSAN) to Report Q1 Earnings: What's in the Cards?

Zosano (ZSAN) is set to provide updates on the development path ahead for its lead candidate, M207, when it reports earnings results for first-quarter 2022.

Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Biogen Inc. (BIIB) closed at $206.94, marking a -0.02% move from the previous day.

Biotech Stock Roundup: GILD's COVID-19 Drug Update, AXSM Down on Regulatory News

Regulatory and pipeline updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.

Incyte (INCY) to Report Q1 Earnings: What's in the Cards?

Incyte's (INCY) top line is likely to have been driven in the first quarter by the sales of its lead drug, Jakafi.

Will Biogen (BIIB) Succeed in Beating Q1 Earnings Estimates?

Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the first quarter.

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) first-quarter sales.

Biogen Inc. (BIIB) Stock Moves -0.92%: What You Should Know

In the latest trading session, Biogen Inc. (BIIB) closed at $218.40, marking a -0.92% move from the previous day.

Prothena (PRTA) Stock Gains 51% in a Year: What Lies Ahead?

Prothena (PRTA) has had a phenomenal run in the past year, primarily due to its promising pipeline for AD.

Why Biogen Inc. (BIIB) is Poised to Beat Earnings Estimates Again

Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Biogen Inc. (BIIB) Stock Moves -0.67%: What You Should Know

In the latest trading session, Biogen Inc. (BIIB) closed at $212.55, marking a -0.67% move from the previous day.

INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate

INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.

Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know

In the latest trading session, Biogen Inc. (BIIB) closed at $214.75, marking a +1.47% move from the previous day.